Vivos Therapeutics Inc
NASDAQ:VVOS
Intrinsic Value
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). [ Read More ]
The intrinsic value of one VVOS stock under the Base Case scenario is 27.31 USD. Compared to the current market price of 4.83 USD, Vivos Therapeutics Inc is Undervalued by 82%.
Valuation Backtest
Vivos Therapeutics Inc
Run backtest to discover the historical profit from buying and selling VVOS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Vivos Therapeutics Inc
Current Assets | 2m |
Cash & Short-Term Investments | 990k |
Receivables | 230k |
Other Current Assets | 770k |
Non-Current Assets | 8.3m |
PP&E | 4.8m |
Intangibles | 3.3m |
Other Non-Current Assets | 310k |
Current Liabilities | 7.2m |
Accounts Payable | 1.5m |
Accrued Liabilities | 2.4m |
Other Current Liabilities | 3.3m |
Non-Current Liabilities | 3.1m |
Other Non-Current Liabilities | 3.1m |
Earnings Waterfall
Vivos Therapeutics Inc
Revenue
|
14.5m
USD
|
Cost of Revenue
|
-5.8m
USD
|
Gross Profit
|
8.7m
USD
|
Operating Expenses
|
-27.8m
USD
|
Operating Income
|
-19.1m
USD
|
Other Expenses
|
3.7m
USD
|
Net Income
|
-15.4m
USD
|
Free Cash Flow Analysis
Vivos Therapeutics Inc
What is Free Cash Flow?
VVOS Profitability Score
Profitability Due Diligence
Vivos Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Vivos Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
VVOS Solvency Score
Solvency Due Diligence
Vivos Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Vivos Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VVOS Price Targets Summary
Vivos Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for VVOS is 7.27 USD with a low forecast of 6.06 USD and a high forecast of 8.66 USD.
Ownership
VVOS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VVOS Price
Vivos Therapeutics Inc
Average Annual Return | -54.2% |
Standard Deviation of Annual Returns | 18.59% |
Max Drawdown | -99% |
Market Capitalization | 6.4m USD |
Shares Outstanding | 1 331 980 |
Percentage of Shares Shorted | 2.04% |
VVOS News
Last Important Events
Vivos Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Vivos Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Highlands Ranch, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The firm's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.
Contact
IPO
Employees
Officers
The intrinsic value of one VVOS stock under the Base Case scenario is 27.31 USD.
Compared to the current market price of 4.83 USD, Vivos Therapeutics Inc is Undervalued by 82%.